Doximity Inc (DOCS)vsMerck & Company Inc (MRK)
DOCS
Doximity Inc
$25.58
+3.52%
HEALTHCARE · Cap: $4.35B
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 10054% more annual revenue ($66.57B vs $655.57M). DOCS leads profitability with a 25.5% profit margin vs 4.8%. DOCS appears more attractively valued with a PEG of 0.59. DOCS earns a higher WallStSmart Score of 59/100 (C).
DOCS
Buy59
out of 100
Grade: C
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+50.3%
Fair Value
$52.21
Current Price
$25.58
$26.63 discount
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 21 in profit
Keeps 26 of every $100 in revenue as profit
Growing faster than its price suggests
Strong operational efficiency at 21.5%
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Moderate valuation
Weak financial health signals
Earnings declined 51.9%
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : DOCS
The strongest argument for DOCS centers on Debt/Equity, Altman Z-Score, Return on Equity. Profitability is solid with margins at 25.5% and operating margin at 21.5%. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : DOCS
The primary concerns for DOCS are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
DOCS profiles as a mature stock while MRK is a value play — different risk/reward profiles.
DOCS carries more volatility with a beta of 1.25 — expect wider price swings.
DOCS is growing revenue faster at 7.3% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
DOCS scores higher overall (59/100 vs 36/100), backed by strong 25.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Doximity Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Doximity, Inc. (Ticker: DOCS) is a U.S. healthcare technology company that operates a digital platform tailored for medical professionals. The company’s cloud-based network provides secure communication and collaboration tools, telemedicine services, clinical workflow solutions, and access to medical news, research, and career-management features for physicians, nurse practitioners, physician assistants, and other clinicians. Headquartered in San Francisco, California, Doximity’s Class A common stock trades on the New York Stock Exchange under the ticker DOCS.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?